Insights into new targets and promising treatments for musculoskeletal disease
Great progress has been made in the understanding of the genes and molecular pathways that contribute to the pathogenesis of bone and muscle diseases. As a result of these advances, several new molecular targets have been identified for drug design – knowledge which is being harnessed for the development of new treatment options for sarcopenia and metabolic bone diseases such as osteoporosis, hypophosphataemic rickets, and hypophosphatasia.
A special issue of 'Calcified Tissue International and Musculoskeletal Research' now highlights some of the most notable advances that have occurred in this fast developing area in seven insightful reviews.
The issue includes the following editorial and reviews:
Editorial: New targets and new treatments for musculoskeletal disease
S. Ralston, R. Rizzoli
Pharmacologic Options for the Treatment of Sarcopenia
John E. Morley
FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism
Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures
E. F. Nemeth, W. G. Goodman
Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies
Pedro Esbrit, Sabina Herrera, Sergio Portal-Núñez, Xavier Nogués, Adolfo Díez-Pérez
Sclerostin inhibition in the management of osteoporosis
Natasha M. Appelman-Dijkstra, Socrates E. Papapoulos
Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis
Le T. Duong, Albert T. Leung, Bente Langdahl
Alkaline Phosphatase and Hypophosphatasia
José Luis Millán, Michael P. Whyte
All papers will be freely accessible from April 6 – 22, 2016
Prof. Stuart Ralston, Arthritis Research UK Chair of Rheumatology and Clinical Director of the Rheumatology Service at the University of Edinburgh, stated, "These invited reviews by leading experts in the field will help interested clinicians gain a comprehensive understanding of this complex and fast moving area of research, with its related advances in drug development. The good news is that many of the new therapeutic options discussed in the reviews may be available in the not-too-distant future, offering patients a greater choice of effective treatments."
About Calcified Tissue International & Musculoskeletal Research:
This peer-reviewed journal publishes original preclinical, translational and clinical research, and reviews concerning the structure and function of bone, and other musculoskeletal tissues in living organisms, as well as clinical studies of musculoskeletal disease. It includes studies of cell biology, molecular biology, intracellular signaling, and physiology, as well as research into the hormones, cytokines and other mediators that influence the musculoskeletal system. The journal also publishes clinical studies of relevance to bone disease, mineral metabolism, muscle function, and musculoskeletal interactions. The 2014 Impact Factor has increased to 3.272.
Editors in Chief: Stuart Ralston and René Rizzoli; Musculoskeletal Research Section Editor: Roger Fielding. https://link.springer.com/journal/223
> Get free or low-cost access to IOF scientific journals via the IOF website (sign in or become a member at http://www.iofbonehealth.org/become-member )
The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers, leading companies, as well as more than 230 patient, medical and research societies, work together to make bone, joint and muscle health a worldwide heath care priority. http://www.iofbonehealth.org / http://www.facebook.com/iofbonehealth / https://twitter.com/iofbonehealth